MedTrace Logo

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

NCT02687542 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2020-11-23

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.

Conditions

  • Parkinson Disease

Interventions

DRUG

Placebo

Placebo

DRUG

PF-06649751 low dose (1 mg QD)

PF-06649751 low dose (1 mg QD)

DRUG

PF-06649751 middle dose 1 (3 mg QD)

PF-06649751 lower middle dose 1 (3 mg QD)

DRUG

PF-06649751 middle dose 2 (7 mg QD)

PF-06649751higher middle dose 2 (7 mg QD)

DRUG

PF-06649751 high dose (15 mg QD)

PF-06649751 high dose (15 mg QD)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-03
Primary Completion
2017-11-10
Completion
2017-11-10
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • Germany
  • Japan
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02687542 on ClinicalTrials.gov